Use of a polysaccharide mixture for treating hyperglycemia
Disclosed herein is a novel use of a polysaccharide mixture for the treatment of hyperglycemia and/or disorders related thereto (e.g., diabetes mellitus). The polysaccharide mixture comprises about 30-50% (wt %) of β(1→3) glucan and β(1→6) glucan, and has a molecular weight of at least 500,000. The polysaccharide mixture may be administered to a subject suffering from hyperglycemia in a dose of about 1 to 1,000 mg/Kg to ameliorate or alleviate symptoms associated with hyperglycemia.
1. A method for the prophylaxis and/or treatment of type II diabetes in a subject comprising administering to the subject a dipeptidyl peptidase-4 (DPP-4) inhibitor and a polysaccharide mixture; wherein the DPP-4 inhibitor is gliptin, and the polysaccharide mixture is derived from Ganoderma lucidum mycelium and has a molecular weight of at least 2,500,000 and about 40% (wt %) of β (1→3) glucan and β (1→6) glucan, and the polysaccharide mixture is administered in an amount of about 1 to 1,000 mg/Kg to ameliorate or alleviate symptoms associated with type II diabetes.
2. The method of claim 1 , wherein the gliptin is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, dutogliptin, and omarigliptin.
3. The method of claim 1 , wherein the polysaccharide mixture is administered orally, intravenously, intramuscularly, subcutaneously, transmucosally, or intrarectally.
4. The method of claim 1 , wherein the polysaccharide mixture is administered to the subject in the amount of about 10 to 800 mg/Kg.
5. The method of claim 1 , wherein the subject is a human.